

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Town Health International Medical Group Limited**  
**康健國際醫療集團有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 3886)**

**(1) APPOINTMENT OF DIRECTORS;**  
**(2) CHANGE OF CHAIRMAN;**  
**(3) RESIGNATION OF**  
**INDEPENDENT NON-EXECUTIVE DIRECTOR;**  
**AND**  
**(4) WITHDRAWAL OF RESOLUTION AT THE**  
**SPECIAL GENERAL MEETING**

The Board is pleased to announce that with effect from 15 December 2023:

- (1) each of Mr. Choi Ka Tsan Karson and Dr. Fok Siu Wing Dominic has been appointed as an executive Director;
- (2) each of Ms. Lee Wai Ling Linda and Ms. Lau Suk Hing Clara has been appointed as a non-executive Director;
- (3) each of Mr. Chan Wai Kan, Mr. Cheung Ka Ming and Mr. Tsui Wing Cheong Sammy has been appointed as an independent non-executive Director;
- (4) Dr. Wong Chun Wa has resigned as the Chairman;

(5) Mr. Choi Ka Tsan Karson has been appointed as the Chairman; and

(6) Mr. Hung Hing Man has resigned as an independent non-executive Director.

The Board also announces that as a result of the resignation of Mr. Hung Hing Man, the ordinary resolution numbered 9 as set out in the Circular and the SGM Notice is no longer applicable and will not be put forward for consideration and approval by the Shareholders at the SGM.

Reference is made to (i) the circular (“**Circular**”) of Town Health International Medical Group Limited (“**Company**”) dated 4 December 2023 in relation to the Proposed Appointment and the Proposed Removal to be approved by the Shareholders at the SGM to be held on 12 January 2024; and (ii) the notice (“**SGM Notice**”) of the SGM dated 4 December 2023. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular and the SGM Notice.

## **APPOINTMENT OF DIRECTORS**

The Board is pleased to announce that with effect from 15 December 2023, (1) each of Mr. Choi Ka Tsan Karson (“**Mr. Choi**”) and Dr. Fok Siu Wing Dominic (“**Dr. Fok**”) has been appointed as an executive Director; (2) each of Ms. Lee Wai Ling Linda (“**Ms. Lee**”) and Ms. Lau Suk Hing Clara (“**Ms. Lau**”) has been appointed as a non-executive Director; and (3) each of Mr. Chan Wai Kan (“**Mr. Chan**”), Mr. Cheung Ka Ming (“**Mr. Cheung**”) and Mr. Tsui Wing Cheong Sammy (“**Mr. Tsui**”) has been appointed as an independent non-executive Director.

The biographical details of Mr. Choi, Dr. Fok, Ms. Lee, Ms. Lau, Mr. Chan, Mr. Cheung and Mr. Tsui are set out below:

### **(a) Mr. Choi**

Mr. Choi, aged 37. Mr. Choi graduated from University of Southern California, the United States with a degree of bachelor of Arts in International Relations. Mr. Choi has been admitted to Honorary University Fellowship of the University of Hong Kong in October 2023.

Mr. Choi has been an independent non-executive director of Sing Tao News Corporation Limited (“**Sing Tao**”), a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 1105) since 2021 and has been redesignated as an executive director and the co-chairman with effect from 30 May 2022. Mr. Choi is currently the vice-chairman of Early Light Industrial Company Limited (“**Early Light**”), the founder and chairman of Unique Timepieces Watches Group Limited and the chairman of Fastwheel Motors Group Limited. Early Light is the world’s largest toys manufacturer. Under the leadership of Mr. Choi, Early Light has developed diversified businesses, including the industries of toys manufacturing, shopping mall development, property rental and management, luxury watches retail, motors sales and maintenance, bioplastic production and education.

Mr. Choi is a deputy director of The Population, Resources and Environment Committee of the Chinese People’s Political Consultative Conference and a member of the National Committee of the Chinese People’s Political Consultative Conference. Mr. Choi also serves as a member of the Court of the University of Hong Kong, members of various government advisory committees and leaders of social groups.

Mr. Choi was a director of (i) BioLogiQ Trading Limited, a private company incorporated in Hong Kong, engaged in trading of chemicals and allied products and dissolved by deregistration on 11 November 2022 under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (“**Chapter 622**”); (ii) Global World Investments Holding Limited, a private company incorporated in Hong Kong, engaged in investment and dissolved by deregistration on 4 August 2023 under Chapter 622; (iii) May Eleven Limited, a private company incorporated in Hong Kong, engaged in sale of candies and dissolved by deregistration on 6 June 2014 under the then prevailing Companies Ordinance (Chapter 32 of the Laws of Hong Kong) (“**Chapter 32**”); and (iv) Orient Development International Limited, a private company incorporated in Hong Kong, engaged in trading of plastic dolls and accessories and dissolved by deregistration on 2 April 2015 under Chapter 622. Mr. Choi has confirmed that BioLogiQ Trading Limited, Global World Investments Holding Limited, May Eleven Limited and Orient Development International Limited were inactive and solvent prior to their respective dissolutions.

Mr. Choi has entered into a letter of appointment with the Company as an executive Director and the chairman of the Company (“**Chairman**”) for a term commencing from 15 December 2023 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment, Mr. Choi will be entitled to an emolument of HK\$200,000 per month, which was determined by the Board with reference to his duties and responsibilities with the Company, the Company’s remuneration policy and the prevailing market conditions.

Mr. Choi is the son of Dr. Choi Chee Ming (“**Dr. Choi**”). As at the date of this announcement, Dr. Choi owns 49.9% of Broad Idea International Limited, an investment company holding 1,418,576,764 Shares, representing approximately 20.94% of the issued capital of the Company, and a substantial shareholder (as defined in the Listing Rules) of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Choi (i) does not hold any other position with the Company or other members of the Group; (ii) does not hold any other major appointment and professional qualification; (iii) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules).

As at the date of this announcement, Mr. Choi does not have any interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“**SFO**”).

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Choi as an executive Director and the Chairman that need to be brought to the attention of the Shareholders.

**(b) Dr. Fok**

Dr. Fok, aged 63. Dr. Fok received a Bachelor of Medicine and Bachelor of Surgery from the University of Hong Kong in 1985, a Diploma in Family Medicine from The Chinese University of Hong Kong in 1992, and was admitted as a Fellow of the Royal Australian College of General Practitioners and a Fellow of the Hong Kong College of General Practitioners both in 1996. Dr. Fok has served in the Department of Community and Family Medicine (“**DCFM**”) of The Chinese University of Hong Kong, which was later merged with the School of Public Health to establish the School of Public Health and Primary Care (“**SPHPC**”) at The Chinese University of Hong Kong, successively as an honorary associate professor from 1996 to 1997, an adjunct assistant professor from 1997 to 2000 and from 2002 to 2003, an honorary clinical assistant professor from 2003 to 2007 and a clinical assistant professor (honorary) from 2007 to 2010. Since 2010, Dr. Fok has served as a clinical assistant professor (honorary) in SPHPC at The Chinese University of Hong Kong. Dr. Fok has served as an honorary clinical assistant professor in family medicine at the University of Hong Kong since 2014.

Dr. Fok is a registered doctor with the Medical Council of Hong Kong and has more than 30 years of practicing experience. Dr. Fok has served in the Group as a registered medical practitioner since 1999.

Dr. Fok has entered into a letter of appointment with the Company as an executive Director for a term commencing from 15 December 2023 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment, Dr. Fok will be entitled to an emolument of HK\$20,000 per month, which was determined by the Board with reference to his duties and responsibilities with the Company, the Company’s remuneration policy and the prevailing market conditions. Pursuant to the service agreement entered into between Dr. Fok and Town Health Medical & Dental Services Limited (“**Town Health Medical**”), a wholly-owned subsidiary of the Company (as amended from time to time), Dr. Fok is entitled to basic salary of HK\$110,000 per month, which was determined with reference to his duties and responsibilities with the Group and the prevailing market conditions, and monthly performance bonus determined by reference to the financial performance of his medical practice in Town Health Medical.

Save as disclosed above, as at the date of this announcement, Dr. Fok (i) does not hold any other position with the Company or other members of the Group; and (ii) does not hold any other major appointment and professional qualification.

As at the date of this announcement, Dr. Fok (i) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any interests in the Shares within the meaning of Part XV of the SFO; and (iii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules).

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Dr. Fok as an executive Director that need to be brought to the attention of the Shareholders.

**(c) Ms. Lee**

Ms. Lee, aged 66. Ms. Lee obtained a Bachelor of Arts from the University of Toronto in Canada in 1980, a Professional Diploma in Management and Marketing for Business Events from the Hong Kong Productivity Council and the Hong Kong Exhibition & Convention Industry Association Limited in 2003 and a Master of Science in Human Resources Management and Development from the University of Leicester in the United Kingdom in 2013.

Ms. Lee has extensive experience in corporate human resources and corporate management. Ms. Lee has served as a vice president of responsible sourcing in BioLogiQ Elite (HK) Ltd. since 4 June 2019. Ms. Lee served the Vocational Training Council from October 1998 to March 2019 with her last position as the deputy head of the human resources division, and the personnel and administration manager of Early Light from June 1995 to June 1997.

Ms. Lee has entered into a letter of appointment with the Company as a non-executive Director for a term commencing from 15 December 2023 to 31 December 2024, and she will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment, Ms. Lee will be entitled to an emolument of HK\$16,000 per month, which was determined by the Board with reference to her duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

Ms. Lee is the sister of the wife of Dr. Choi.

Save as disclosed above, as at the date of this announcement, Ms. Lee (i) does not hold any other position with the Company or other members of the Group; (ii) does not hold any other major appointment and professional qualification; and (iii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules).

As at the date of this announcement, Ms. Lee (i) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (ii) does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Lee as a non-executive Director that need to be brought to the attention of the Shareholders.

**(d) Ms. Lau**

Ms. Lau, aged 62. Ms. Lau has served Early Light International (Holdings) Limited ("**Early Light International**") since June 1992. She has served as the personal assistant to the chairman of Early Light International and also serves as a director of several companies of Early Light International in Hong Kong and Mainland China.

Ms. Lau has extensive experience in assisting the chairman of Early Light International in handling the group's real estate development, manufacturing and retail businesses for many years, including internal supervision, finance and general daily management and operations.

Ms. Lau was a director of (i) Halewinner Retail Holdings Limited, a private company incorporated in Hong Kong, engaged in retail and dissolved by deregistration on 24 January 2020 under Chapter 622; (ii) Honourable Rich Limited, a private company incorporated in Hong Kong, engaged in trading of accessories and dissolved by deregistration on 30 October 2020 under Chapter 622; (iii) Master Faith Limited, a private company incorporated in Hong Kong, engaged in retail and dissolved by deregistration on 18 January 2019 under Chapter 622; (iv) Treasure Standard Limited, a private company incorporated in Hong Kong, engaged in retail and dissolved by deregistration on 6 June 2019 under Chapter 622; (v) Try Me (Hong Kong) Limited, a private company incorporated in Hong Kong, engaged in retail and dissolved by deregistration on 26 October 2018 under Chapter 622; (vi) Unique Timepieces (CWB) Company Limited, a private company incorporated in Hong Kong and a retail shop and dissolved by deregistration on 14 September 2018 under Chapter 622; and (vii) United Faith (China) Limited, a private company incorporated in Hong Kong, engaged in investment and dissolved by deregistration on 25 October 2019 under Chapter 622. Ms. Lau has confirmed that Halewinner Retail Holdings Limited, Honourable Rich Limited, Master Faith Limited, Treasure Standard Limited, Try Me (Hong Kong) Limited, Unique Timepieces (CWB) Company Limited and United Faith (China) Limited were inactive and solvent prior to their respective dissolutions.

Ms. Lau has entered into a letter of appointment with the Company as a non-executive Director for a term commencing from 15 December 2023 to 31 December 2024, and she will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment, Ms. Lau will be entitled to an emolument of HK\$16,000 per month, which was determined by the Board with reference to her duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

As at the date of this announcement, Ms. Lau has interests in 241,834,000 Shares within the meaning of Part XV of the SFO.



Save as disclosed above, as at the date of this announcement, Ms. Lau (i) does not hold any other position with the Company or other members of the Group; (ii) does not hold any other major appointment and professional qualification; and (iii) does not have any interests in the Shares within the meaning of Part XV of the SFO.

As at the date of this announcement, Ms. Lau (i) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (ii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules).

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Lau as a non-executive Director that need to be brought to the attention of the Shareholders.

**(e) Mr. Chan**

Mr. Chan, aged 65. Mr. Chan obtained a Bachelor of Science degree in Economics & Accountancy from The City, University of London in the United Kingdom in 1985 and acquired a Master of Business Administration from The Chinese University of Hong Kong in 1999. Mr. Chan is a member of both the Institute of Chartered Accountants in England and Wales, as well as The Hong Kong Institute of Certified Public Accountants.

Presently, Mr. Chan holds the position of executive director at Shui On Investment Company Limited. Furthermore, he has been serving as a non-executive director of SOCAM Development Limited, a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 983), since 1 September 2023. Prior to his current roles, Mr. Chan had the privilege of serving as the managing director of property development department of Early Light International. He also held the position of director of finance at Shui On Land Limited, a company listed on the Main Board of the Stock Exchange (stock code: 272). Additionally, Mr. Chan had contributed his expertise as the chief financial officer of Tishman Speyer in China and the chief financial officer at Playmates Interactive Entertainment Limited (now known as Playmates Holdings Limited), a company listed on the Main Board of the Stock Exchange (stock code: 635).

Mr. Chan has entered into a letter of appointment with the Company as an independent non-executive Director for a term commencing from 15 December 2023 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment, Mr. Chan will be entitled to an emolument of HK\$16,000 per month, which was determined by the Board with reference to his duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Chan (i) does not hold any other position with the Company or other members of the Group; (ii) does not hold any other major appointment and professional qualification; and (iii) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas.

As at the date of this announcement, Mr. Chan (i) does not have any interests in the Shares within the meaning of Part XV of the SFO; and (ii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules).

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Chan as an independent non-executive Director that need to be brought to the attention of the Shareholders.

**(f) Mr. Cheung**

Mr. Cheung, aged 61. Mr. Cheung received a Bachelor of Science degree from the University of Hong Kong in 1983 and a Master of Business Administration from the City University, London, United Kingdom in 1989.

Mr. Cheung is experienced in investment and financial services from his previous services in local and multinational financial institutions.

Mr. Cheung has entered into a letter of appointment with the Company as an independent non-executive Director for a term commencing from 15 December 2023 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment, Mr. Cheung will be entitled to an emolument of HK\$16,000 per month, which was determined by the Board with reference to his duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Cheung (i) does not hold any other position with the Company or other members of the Group; and (ii) does not hold any other major appointment and professional qualification.

As at the date of this announcement, Mr. Cheung (i) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any interests in the Shares within the meaning of Part XV of the SFO; and (iii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules).

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Cheung as an independent non-executive Director that need to be brought to the attention of the Shareholders.

**(g) Mr. Tsui**

Mr. Tsui, aged 58. Mr. Tsui obtained a Master of Business Administration from The Chinese University of Hong Kong. He was also a mentor in the HKU Media Mentorship Program at the Journalism and Media Studies Center of the University of Hong Kong.

Mr. Tsui founded China Tech Global Limited (now known as China Tech Global (Holdings) Limited) ("**China Tech**") in 2014 and then started to run the sanitizing business under BioEm Air Sanitizing Technology Company Limited, which is a subsidiary of China Tech.

Mr. Tsui founded Golden Wealth Technology Limited (“**Golden Wealth**”) in March 2020, and Golden Wealth became the SenseTime innovation partner and the distributor in Hong Kong and Macau of SenseTime Group Limited. Golden Wealth is engaged in provision of artificial intelligence solutions. The clients of Golden Wealth include Disciplined Services and major infrastructures in Hong Kong.

Mr. Tsui was appointed as an executive director and deputy chief executive officer of Celestial Asia Securities Holdings Limited, a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 1049), with effect from October 2013 and was appointed as the chief executive officer of Celestial Asia Securities Holdings Limited with effect from January 2014 to July 2014. Mr. Tsui was an executive director and the chief executive officer of China Outdoor Media Group Limited (now known as National United Resources Holdings Limited), a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 254), from April 2011 to September 2013.

Mr. Tsui was a director of (i) Hayari Curation Company Limited, a private company incorporated in Hong Kong, engaged in provision of marketing consultancy services and dissolved by deregistration on 25 August 2017 under Chapter 622; (ii) Magic Logic By SAS Company Limited, a private company incorporated in Hong Kong, engaged in provision of marketing consultancy services and dissolved by deregistration on 29 March 2019 under Chapter 622; and (iii) Starbase Group Limited, a private company incorporated in Hong Kong and a trading company for paintings and dissolved by striking off on 26 October 2007 under Chapter 32. Mr. Tsui has confirmed that Hayari Curation Company Limited, Magic Logic By SAS Company Limited and Starbase Group Limited were inactive and solvent prior to their respective dissolutions.

Mr. Tsui has entered into a letter of appointment with the Company as an independent non-executive Director for a term commencing from 15 December 2023 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment, Mr. Tsui will be entitled to an emolument of HK\$16,000 per month, which was determined by the Board with reference to his duties and responsibilities with the Company, the Company’s remuneration policy and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Tsui (i) does not hold any other position with the Company or other members of the Group; and (ii) does not hold any other major appointment and professional qualification.

As at the date of this announcement, Mr. Tsui (i) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any interests in the Shares within the meaning of Part XV of the SFO; and (iii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules).

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Tsui as an independent non-executive Director that need to be brought to the attention of the Shareholders.

## **CHANGE OF CHAIRMAN**

The Board announces that with effect from 15 December 2023, (i) Dr. Wong Chun Wa (“**Dr. Wong**”) has resigned as the Chairman due to his other professional commitments which require more of his time; and (ii) Mr. Choi has been appointed as the Chairman.

Dr. Wong has confirmed that he does not have any disagreement with the Board and there is no matter relating to his resignation as the Chairman that needs to be brought to the attention of the Shareholders.

## **RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board announces that subsequent to the despatch of the Circular and the SGM Notice, on 15 December 2023, Mr. Hung Hing Man (“**Mr. Hung**”), an independent non-executive Director, has resigned as an independent non-executive Director (“**Resignation**”) due to his other business engagements which require more of his time and attention.

Mr. Hung has confirmed that he has no disagreement with the Board and there is no other matter relating to the Resignation that needs to be brought to the attention of the Shareholders.

## **WITHDRAWAL OF RESOLUTION AT THE SPECIAL GENERAL MEETING**

As a result of the Resignation, the ordinary resolution numbered 9 as set out in the Circular and the SGM Notice is no longer applicable and will not be put forward for consideration and approval by the Shareholders at the SGM. Save as disclosed above, all other resolutions contained in the Circular and the SGM Notice shall continue to be considered at the SGM.

The proxy form for the SGM already lodged by the Shareholders shall remain valid except that no poll will be conducted or counted for ordinary resolution numbered 9 as set out in the Circular and the SGM Notice.

The Board would like to extend its sincere gratitude to Mr. Hung for his valuable contribution to the Group during his tenure of office and express its warmest welcome to Mr. Choi, Dr. Fok, Ms. Lee, Ms. Lau, Mr. Chan, Mr. Cheung and Mr. Tsui on their new appointments.

By Order of the Board  
**Town Health International Medical Group Limited**  
**Wong Chi Kit Nelson**  
*Chief Executive Officer and Executive Director*

Hong Kong, 15 December 2023

*As at the date of this announcement, the executive Directors are Mr. Choi Ka Tsan Karson (Chairman), Dr. Wong Chi Kit Nelson (Chief Executive Officer), Dr. Wong Chun Wa, Mr. Ng Ting Chi, Ms. Yao Yuan, Ms. Lau Wai Yee, Susanna and Dr. Fok Siu Wing Dominic; the non-executive Directors are Mr. Hou Jun, Ms. Lee Wai Ling Linda and Ms. Lau Suk Hing Clara; and the independent non-executive Directors are Mr. Ho Kwok Wah, George, MH, Mr. Yu Xuezhong, Dr. Xu Weiguo, Mr. Chui Tsan Kit, Mr. Han Wenxin, Mr. Tang Chi Kong, Mr. Chan Wai Kan, Mr. Cheung Ka Ming and Mr. Tsui Wing Cheong Sammy.*